Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:NVRO
Previous Symbol
CUSIPN/A
Phone650-251-0005
Debt
Debt-to-Equity Ratio0.62
Current Ratio8.05
Quick Ratio6.31
Price-To-Earnings
Trailing P/E Ratio-31.02
Forward P/E Ratio-25.46
P/E GrowthN/A
Sales & Book Value
Annual Sales$326.67 million
Price / Sales3.50
Cash FlowN/A
Price / CashN/A
Book Value$8.41 per share
Price / Book4.51
Profitability
EPS (Most Recent Fiscal Year)($1.25)
Net Income$-36,650,000.00
Net Margins-11.64%
Return on Equity-17.89%
Return on Assets-9.76%
Miscellaneous
Employees676
Outstanding Shares30,160,000
Market Cap$1.22 billion
OptionableOptionable
Nevro (NYSE:NVRO) Frequently Asked Questions
What is Nevro's stock symbol?
Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
How were Nevro's earnings last quarter?
Nevro Corp (NYSE:NVRO) announced its quarterly earnings results on Monday, November, 5th. The medical equipment provider reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.07. The medical equipment provider had revenue of $95.60 million for the quarter, compared to analyst estimates of $94.29 million. Nevro had a negative net margin of 11.64% and a negative return on equity of 17.89%. The company's revenue for the quarter was up 16.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.21) EPS. View Nevro's Earnings History.
When is Nevro's next earnings date?
What guidance has Nevro issued on next quarter's earnings?
Nevro issued an update on its FY 2018 earnings guidance on Monday, November, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $385-390 million, compared to the consensus revenue estimate of $385.81 million.
What price target have analysts set for NVRO?
9 Wall Street analysts have issued 1 year price objectives for Nevro's shares. Their predictions range from $43.00 to $105.00. On average, they anticipate Nevro's stock price to reach $64.1111 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price. View Analyst Price Targets for Nevro.
What is the consensus analysts' recommendation for Nevro?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nevro.
Has Nevro been receiving favorable news coverage?
News coverage about NVRO stock has trended very positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nevro earned a media sentiment score of 3.1 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Nevro's key competitors?
Some companies that are related to Nevro include Insulet (PODD), Penumbra (PEN), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Novocure (NVCR), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), AtriCure (ATRC), Luminex (LMNX) and K2M Group (KTWO).
Who are Nevro's key executives?
Nevro's management team includes the folowing people:
- Mr. Rami Elghandour, Pres, CEO & Director (Age 39)
- Mr. Andrew H. Galligan, Chief Financial Officer (Age 62)
- Mr. Patrick Schmitz, VP of Operations (Age 58)
- Mr. Doug Alleavitch, VP of Quality (Age 57)
- Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 44)
Who are Nevro's major shareholders?
Nevro's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.00%), Franklin Resources Inc. (7.66%), Jennison Associates LLC (4.98%), Point72 Asset Management L.P. (4.94%), Janus Henderson Group PLC (4.12%) and JPMorgan Chase & Co. (3.49%). Company insiders that own Nevro stock include Andrew H Galligan, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.
Which institutional investors are selling Nevro stock?
NVRO stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Wells Fargo & Company MN, Alliancebernstein L.P., Credit Suisse AG, Janus Henderson Group PLC, Kornitzer Capital Management Inc. KS and BlackRock Inc.. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan and Wilfred E Jaeger. View Insider Buying and Selling for Nevro.
Which institutional investors are buying Nevro stock?
NVRO stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Franklin Resources Inc., Gabelli Funds LLC, TIAA CREF Investment Management LLC, Bellevue Group AG, Sio Capital Management LLC, Pictet Asset Management Ltd. and Los Angeles Capital Management & Equity Research Inc.. View Insider Buying and Selling for Nevro.
How do I buy shares of Nevro?
Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nevro's stock price today?
One share of NVRO stock can currently be purchased for approximately $38.77.
How big of a company is Nevro?
Nevro has a market capitalization of $1.22 billion and generates $326.67 million in revenue each year. The medical equipment provider earns $-36,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Nevro employs 676 workers across the globe.
What is Nevro's official website?
How can I contact Nevro?
Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]
MarketBeat Community Rating for Nevro (NYSE NVRO)
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
